Solid Biosciences Inc.
SLDB · XNASCIK 1707502fmd_0BWVGE93T3CGRCFYX6CJBDAXRBManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 14 | 8 | – | – | – |
| Research and development | 20 | 40 | 58 | 95 | 65 | 59 | 78 | 77 | 96 | 140 |
| Total operating expenses | 26 | 55 | 76 | 119 | 88 | 86 | 115 | 104 | 130 | 179 |
| Operating income | (26) | (55) | (76) | (119) | (88) | (72) | (106) | (104) | (130) | (179) |
| Interest expense | – | – | – | – | – | – | – | 0 | 0 | (0) |
| Interest and investment income | 0 | 0 | 1 | 2 | 0 | 0 | 3 | 8 | 9 | 10 |
| Other non-operating income (expense) | 2 | 2 | 1 | 2 | 0 | 0 | 20 | 8 | 5 | 5 |
| Income before taxes | – | – | – | – | – | – | – | – | (125) | (174) |
| Income tax expense | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (125) | (174) |
| Net income | (22) | (52) | (75) | (117) | (88) | (72) | (86) | (96) | (125) | (174) |
| Net income to common shareholders | (17) | (39) | (75) | (117) | – | – | – | – | – | – |